NCT07075484View on ClinicalTrials.gov

A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions
Autoimmune Hemolytic Anemia
Interventions
DRUG

YTS109 cell

Subjects will receive YTS109 cell, and dose escalation will commence at 5E6 cells/kg or the starting dose may be adjusted based on accumulated data.

Trial Locations (1)

Unknown

RECRUITING

Institute of Hematology & Blood Diseases Hospital, China, Tianjin

All Listed Sponsors
collaborator

Institute of Hematology & Blood Diseases Hospital, China

OTHER

lead

China Immunotech (Beijing) Biotechnology Co., Ltd.

INDUSTRY